Omanyano ovanhu koikundaneki yomalungula kashili paveta, Commisiner Sakaria takunghilile
Veronika Haulenga
Omanyano ovanhu koikundaneki yomalungula kashili paveta, Commisiner Sakaria takunghilile
Veronika Haulenga
Listeners:
Top listeners:
Omanyano ovanhu koikundaneki yomalungula kashili paveta, Commisiner Sakaria takunghilile Veronika Haulenga
A six-monthly HIV prevention injection containing lenacapavir has been confirmed effective in two pivotal studies. The first study, PURPOSE 1, showed no HIV infections among two-thousand-134 participants, while the second, PURPOSE 2, reported two infections among two-thousand-179 participants. This translates to a 96-percent reduction in HIV infections compared to background incidence. Gilead Sciences plans to file for regulatory approval to market lenacapavir for prevention.
Separately, during a press briefing on Monday, the U.S. Department of State’s Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, Ambassador John Nkengasong, discussed PEPFAR’s Aids response plan for Africa. Nkengasong asked governments to take ownership and lead the way in the HIV/AIDS response.
Audio Player
Notifications
